Last updated: 2026-09-09 04:53:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Neumora Therapeutics, Inc. (NMRA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.26, with a market capitalization of $246.14M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.83 to $3.65. This page covers its latest market performance, valuation, price trends and company information.
$246.14M | |
$1.29 | |
$21.00 | |
$0.61 | |
$1.31 | |
705.66K | |
1.88M | |
-- | |
$3.65 | |
$0.83 | |
-- | |
-- |
Neumora Therapeutics, Inc. (NMRA) last closed at $1.31 as of 2026-09-08 23:56:00, unchanged from the previous close of $1.31.
During the latest regular trading session, NMRA traded between $0.61 and $21.00, with a volume of 705.66K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Neumora Therapeutics, Inc. (NMRA) moved from $1.48 to $1.26, representing a decline of 15.20% ($0.23).
The stock traded between $1.25 and $1.58 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 551.93 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 15.1%
NMRA is currently trading at $1.26, placing it 15.1% of the way from its 52-week low of $0.83 to its 52-week high of $3.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 63 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Neumora Therapeutics, Inc. (NMRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.